

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE: Application of Jodi Marie MAGLICH et al.

Serial No.: 10/506,647

Art Unit: 1647

Filing Date: September 3, 2004

Examiner: Shafer, Shulamith H.

For: *Compositions and Methods for
Regulating Thyroid Hormone
Metabolism and Cholesterol and
Lipid Metabolism via the Nuclear
Receptor Car*

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Applicants request that the references identified on Form PTO-1449 appended hereto be considered by the Examiner and officially made of record in accordance with the provisions of 37 CFR 1.97

- ☒ Copies of the references are enclosed
- ☐ Copies of the references were submitted in parent application Serial No. _____.
(37 CFR 1.98(d))
- ☒ A copy of the European Search Report which issued on European Application No. 03719339.8 is submitted herewith.

- A. ☒ The Information Disclosure Statement submitted herewith is being filed within three months of the filing date of the above application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever event occurs last. 37 CFR 1.97(b).

OR

- ☐ **The Information Disclosure Statement submitted herewith is being filed before the mailing of a first office action after the filing of a Request For Continued Examination under 37 C.F.R. 1.114 (37 C.F.R. 1.97(b)(4)).**

- B. ☐ The Information Disclosure Statement transmitted herewith is being filed **after** three months of the filing date of the above application or the date of entry into the national stage as set forth in § 1.491 of an international application or after the mailing date of the first Office Action on the merits, whichever event occurred last, but **before** the mailing date of either:
- (1) a final action under § 1.113 or
 - (2) a notice of allowance under § 1.311,
- whichever occurs first.

- ☐ Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.

- ☐ Applicant elects the option to pay the fee set forth in 37 CFR 1.17(p) for submission of an Information Disclosure Statement under § 1.97(c) (\$180.00).

- C. ☐ The Information Disclosure Statement transmitted herewith is being filed **after** a final action under § 1.113, or a notice of allowance under § 1.311, whichever occurs first, but before the payment of the issue fee. Also enclosed is a copy of the International Search Report which Issued on International Publication No.

In accordance with the requirements of 37 CFR 1.97(d):

- ☐ Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement. **[or]**
- ☐ Applicant hereby certifies that no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to my knowledge after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of this statement; and
- ☐ The petition fee set forth in § 1.17(i)(1) (\$180.00) is submitted herewith.

☒ Please charge any required fees to Deposit Account No.07-1392.

☐ A duplicate copy of this paper is attached.

Respectfully Submitted,

/Michael M. Conger/
Michael M. Conger
Attorney of Record
Registration No. 43,562

Date: July 18, 2006
GlaxoSmithKline
Corporate Intellectual Property
5 Moore Drive, P.O. Box 13398
Research Triangle Park, NC 27709-3398
Telephone: (919) 483-2474
Facsimile: (919) 483-7988

Form PTO-1449	U.S. Department of Commerce Patent and Trademark Office	ATTY DOCKET NO. PU4591	SERIAL NO. 10/506,647
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use several sheets if necessary)</i>		APPLICANT Jodi Marie MAGLICH et al.	
		FILING DATE September 3, 2004	GROUP 1647

U.S. PATENT DOCUMENTS

Examiner Initials		Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate

FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Subclass	Translation Yes No	

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc)

	1	MAGLICH J.M ET AL; The nuclear receptor CAR is a regulator of thyroid hormone metabolism during caloric restriction; J. BIOL. CHEM.; 7 MAY 2004; VOL 279 No. 19; 19832-19838;
	2	QATANANI M ET AL; Role of the constitutive androstane receptor in xenobiotic-induced thyroid hormone metabolism; ENDOCRINOL; 24 November 2004; 146, no. 3; 995-1002;
	3	UEDA A ET AL; Diverse roles of the nuclear orphan receptor CAR in regulating hepatic genes in response to phenobarbital; MOL. PHARMACOL; 1 January 2002; 61, no. 1; 1-6;

Examiner Signature	Date Considered
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	